Status:
COMPLETED
N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Liver Cirrhoses
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Contrast induced nephropathy has an incidence of 7-11 % in patients undergoing Contrast imaging for various conditions. The risk associated with the development of CIN are still under evaluation. Even...
Eligibility Criteria
Inclusion
- Age-18-70 years
- Normal kidney parameters (Creatinine below \<1 ,Creatinine clearance \>60)
- Cirrhosis of liver
- eGFR\>60ml/min
Exclusion
- Chronic kidney disease
- H/o anaphylaxis to contrast
- Prior h/o AKI
- GFR\<60 ML/MIN
- Prior H/o TACE/HVPG /Contrast ECHO in the last 4 weeks
Key Trial Info
Start Date :
December 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03759158
Start Date
December 1 2018
End Date
January 15 2019
Last Update
November 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070